FDA approves first postpartum depression drug

For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. The FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth. CNN's Dr. Sanjay Gupta reports.

Posted: Mar 20, 2019 8:37 AM


For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians.

On Tuesday, the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth.

The treatment is administered as a single 60-hour IV drip and was found to have mild side effects, such as headache, dizziness or excessive sleepiness. Yet some women may face barriers accessing this type of treatment, as it requires 60 hours of time. The drug will likely be priced around $20,000 to $35,000 per treatment, Sage Therapeutics, the company that developed the drug, confirmed.

The initial list price for Zulresso in the United States will be $7,450 per vial, resulting in a projected average course of therapy cost of $34,000 per patient before discounts, according to the company. The actual number of vials used before discounts can vary from patient to patient.

The medication will be available in June, said Dr. Jeff Jonas, CEO of the Massachusetts-based biopharmaceutical company that developed the drug. The drug will be available only through a restricted program called the Zulresso Risk Evaluation and Mitigation Strategy (REMS) Program that requires the drug be administered by a health care provider in a certified health care facility, the FDA said in a news release announcing the approval.

"There are no FDA approved antidepressants for postpartum depression, so approval of the first medication of its kind is a breakthrough for patients," said Dr. Kristina Deligiannidis, the director of Women's Behavioral Health at Northwell Health's Zucker Hillside Hospital in New York, who was involved in two of the drug's clinical trials as a researcher.

Without any treatment, postpartum depression can last for months or even years, according to the National Institute of Mental Health. Studies showed the brexanolone was effective regardless of when postpartum depression symptoms began.

In the United States, it's estimated that every year, more than 400,000 infants are born to mothers who are depressed. Treatment options for postpartum depression have included counseling or therapy with a mental health professional and antidepressant medications, but no antidepressant medication has been specifically FDA-approved to treat postpartum depression. Also, antidepressant medications generally don't provide an immediate relief of symptoms and may take several weeks to help.

"Brexanolone in phase II and III trials demonstrated rapid antidepressant effects," said Deligiannidis, who is also an associate professor at the Feinstein Institute for Medical Research and member of the Anxiety and Depression Association of America.

Those effects are something that Stephanie Hathaway, a Connecticut-based mother of two, knows well.

A 'breakthrough' drug gets tested

When Hathaway brought her first baby home from the hospital, she was just as excited and nervous as most new moms -- but she also experienced crying spells and troubling thoughts that she couldn't shake.

"The first two weeks I was crying excessively," Hathaway said. At first, her husband and she thought her tears were from "the baby blues," a feeling of sadness or emptiness after giving birth that goes away within a few days.

"But after that I had intrusive thoughts," she said. "Those were, 'Your daughter deserves a better mom,' and 'Your husband deserves a better wife.' "

Then Hathaway knew she needed help when one day she was holding her daughter and she feared what she might do to herself once she put her baby down.

That year, in 2014, Hathaway was diagnosed with postpartum depression and was treated with traditional antidepressant medications, which she said helped "over time."

A few years later, in 2017, Hathaway had a second child, and was prescribed the same antidepressants during that pregnancy -- but the medications were not helpful in relieving her symptoms.

A friend told Hathaway about clinical trials being conducted to evaluate the effectiveness of brexanolone in treating postpartum depression. Hathaway enrolled in a trial.

"It was a 60-hour infusion and in the first 12 to 18 hours I felt the biggest difference," Hathaway said.

"Those intrusive thoughts that played on repeat in my head, those went away and didn't come back," she said, adding that as a side effect, "I just had one very small instance of standing up and feeling lightheaded."

In 2016, the FDA granted brexanolone a "breakthrough therapy designation" for the treatment of postpartum depression. Such a designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

Results from two phase III trials of brexanolone, conducted across 30 clinical research centers and specialized psychiatric units in the United States, published in the journal The Lancet in August.

The trials, conducted in 2016 and 2017, involved more than 200 women who had symptoms of postpartum depression, which were assessed by standardized research scales. The women were followed up with over 30 days. Sage Therapeutics funded the research.

In those studies, some of the women were given 60-hour IV infusions of smaller or larger doses of brexanolone while others were given a placebo. The researchers found that the women who received brexanolone infusions had "significant and clinically meaningful" reductions in their depression scores.

In the first study, by the end of 60 hours, the average reduction was 19.5 points in the brexanolone group that received smaller doses, and 17.7 points in the brexanolone group that received larger doses, compared with 14 points in the placebo group.

In the second study, which had only one brexanolone group, the average reduction in score was by 14.6 points in the brexanolone group compared with 12.1 points in the placebo group at 60 hours, the researchers found.

Overall, at 60 hours, about 75% of women who received brexanolone were at least 50% improved in their symptoms and about half of women who received brexanolone were no longer clinically depressed, Deligiannidis said.

Among the patients who had a response at 60 hours, 94% did not relapse at the 30-day followup.

The most common side effects included headache among 15.7% of patients; dizziness among 13.6%; and somnolence or excessive sleepiness among 10.7%, the researchers found.

The researchers wrote in the study that their findings "provide strong evidence for the efficacy and safety of brexanolone injection in women with moderate to severe post-partum depression."

Limitations of the studies include that the women were followed only for 30 days, so the duration of treatment effects beyond that were not included in the data.

The treatment also requires 60 hours of an IV -- which, for women without support at home or living in poverty, could be difficult. Low-income mothers are at high risk for postpartum depression. The treatment also could interrupt breastfeeding, and patients are encouraged to discuss the risks and benefits of breastfeeding with their physician.

Additionally in the trials, brexanolone had the most robust effects on women experiencing severe postpartum depression whereas results were more modest among others whose postpartum depression was less severe.

'It potentially sets a new standard for treatment'

"What has been consistent is that brexanolone had a very robust response -- and what's been most exciting to me, in terms of participating in this new drug development, was the rapid onset of response. The drug works quickly," said Dr. Samantha Meltzer-Brody, a professor of mood and anxiety disorders at the University of North Carolina School of Medicine in Chapel Hill, who was a researcher in those phase III trials for the drug.

"My greatest hope is that this increases awareness. What's heartbreaking is the number of women who suffer in silence and do not get the treatment that they need," she said. "People need to reach out and get screened and get treatment, regardless of if treatment is with brexanolone or not."

The clinical data supporting the effectiveness of brexanolone in helping women recover from postpartum depression sheds new light on the neurobiology of the illness, as well as depression during other life periods, said Catherine Monk, professor of medical psychology in obstetrics and gynecology and psychiatry at Columbia University Irving Medical Center and director of research in the women's program in psychiatry at NewYork-Presbyterian/Columbia University Irving Medical Center in New York. Monk was not involved in the drug trials.

Monk, who is also a research scientist at the New York State Psychiatric Institute, added that "because its effects are truly expedited, within days, it potentially sets a new standard for treatment for severe postpartum depression."

Terre Haute
Broken Clouds
90° wxIcon
Hi: 92° Lo: 70°
Feels Like: 96°
Robinson
Scattered Clouds
89° wxIcon
Hi: 91° Lo: 68°
Feels Like: 96°
Indianapolis
Broken Clouds
85° wxIcon
Hi: 93° Lo: 71°
Feels Like: 89°
Rockville
Scattered Clouds
87° wxIcon
Hi: 91° Lo: 70°
Feels Like: 89°
Casey
Clear
89° wxIcon
Hi: 90° Lo: 70°
Feels Like: 92°
Brazil
Broken Clouds
90° wxIcon
Hi: 91° Lo: 70°
Feels Like: 96°
Marshall
Broken Clouds
90° wxIcon
Hi: 91° Lo: 70°
Feels Like: 96°
Fireworks Forecast for Tonight
WTHI Planner
WTHI Temps
WTHI Radar

WTHI Events

 

Illinois Coronavirus Cases

(Widget updates once daily at 7 p.m. CT)

Confirmed Cases: 145750

Reported Deaths: 7005
CountyConfirmedDeaths
Cook917744618
Lake9864421
DuPage9192474
Kane7796274
Will6839320
Winnebago306796
McHenry208897
St. Clair1965137
Kankakee130265
Rock Island99629
Madison99169
Kendall98121
Champaign93012
Boone60221
DeKalb56719
Peoria54628
Sangamon44032
Jackson33519
Randolph2877
Stephenson2755
Ogle2684
McLean26713
Clinton24017
Macon23222
LaSalle22417
Union19319
Whiteside19215
Coles17317
Grundy1695
Iroquois1605
Tazewell1468
Warren1430
Knox1360
Cass1346
Morgan1303
Monroe12913
Williamson1224
Adams1061
Jefferson10617
McDonough10215
Lee982
Henry931
Vermilion772
Pulaski760
Marion680
Perry561
Douglas540
Macoupin543
Livingston502
Jasper477
Jo Daviess461
Montgomery461
Unassigned460
Christian454
Ford371
Jersey351
Woodford342
Bureau292
Franklin270
Menard240
Fayette233
Alexander220
Carroll222
Mason220
Wabash220
Mercer210
Piatt210
Washington210
Johnson200
Hancock191
Moultrie190
Shelby191
Crawford180
Logan160
Clark150
Fulton150
Massac150
Wayne141
Bond131
Effingham131
Schuyler130
Cumberland120
Brown100
Edgar100
De Witt90
Greene90
Marshall90
Saline90
Henderson80
Lawrence70
White60
Hamilton50
Richland40
Stark40
Pike30
Clay20
Edwards20
Gallatin20
Calhoun10
Hardin10
Pope10
Putnam10
Scott10
Out of IL00

Indiana Coronavirus Cases

(Widget updates once daily at 8 p.m. ET)

Confirmed Cases: 46915

Reported Deaths: 2681
CountyConfirmedDeaths
Marion11499683
Lake5053242
Elkhart316443
Allen2717128
St. Joseph186366
Cass16369
Hamilton1518100
Hendricks1386100
Johnson1254118
Porter71237
Tippecanoe6778
Madison64864
Clark63844
Bartholomew58244
Howard56057
LaPorte55326
Kosciusko5124
Vanderburgh4806
Jackson4653
LaGrange4657
Noble45728
Hancock43735
Boone43443
Delaware42949
Marshall4273
Shelby42025
Floyd37144
Morgan32531
Montgomery29320
Grant29026
Clinton2852
Monroe26628
Dubois2646
White26010
Decatur24832
Henry24315
Lawrence23624
Vigo2288
Dearborn22723
Harrison21022
Warrick21029
Greene18432
Miami1812
Jennings17111
Putnam1688
Scott1607
DeKalb1594
Daviess14116
Orange13523
Wayne1346
Perry1279
Steuben1262
Franklin1248
Jasper1142
Ripley1147
Carroll1102
Wabash1102
Fayette987
Newton9710
Whitley884
Starke853
Randolph784
Huntington712
Wells711
Jefferson701
Fulton681
Jay680
Washington661
Knox630
Pulaski621
Clay604
Gibson592
Rush563
Adams481
Benton480
Owen471
Sullivan441
Brown381
Blackford372
Posey360
Spencer351
Fountain302
Tipton301
Crawford290
Switzerland260
Martin220
Parke220
Ohio140
Warren141
Union130
Vermillion130
Pike90
Unassigned0193